Earnings Estimate Revisions for Kyverna Therapeutics, Inc. This company is expected to earn -$3.29 per share for the fiscal year ending December 2024, which represents a year-over-year change of ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

NASDAQ KYTX opened at $3.03 on Thursday. Kyverna Therapeutics has a 1-year low of $2.64 and a 1-year high of $30.60. The business has a 50 day simple moving average of $3.63 and a two-hundred day ...

NEW YORK, NY / ACCESS Newswire / February 2, 2025 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the ...

Cruz reminds investors of the upcoming February 7, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Kyverna ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

EMERYVILLE, Calif., March 3, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients ...

Kyverna Therapeutics, Inc. has a 52-week low of $3.02 and a 52-week high of $35.06. The business’s 50 day moving average is $4.00 and its two-hundred day moving average is $5.48.

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Kyverna ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...